Skip to main content

Table 2 Patient characteristics (randomised patients)

From: Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

  Intra-venous
(n = 9)
Intra-arterial
(n = 10)
Total
(n = 19)
Age, years    
median ((25th, 75th centile) min, max 60 (59,60) 53–66 59 (55,63) 47–67 60 (57,63) 47–67
Karnofsky Performance Status    
Score ≤ 80 3 (33%) 7 (70%) 10 (53%)
Score ≥ 90 6 (67%) 3 (30%) 9 (47%)
Stage    
IVa 2 (22%) 6 (60%) 8 (42%)
IVb 7 (78%) 4 (40%) 11 (58%)
Previous treatment    
  3 (33%)φ 1 (10%)ξ 4 (21%)
Time from diagnosis to randomisation, days    
median ((25th, 75th centile) 84 (60,203) 37 (16,115) 77 (25,177)
min, max 27–316 2–256 2–316
  1. φ one patient each had received: gemcitabine plus oxaliplatin 6 cycles, gemcitabine 8 cycles and gemcitabine 7 cycles
  2. ξgemcitabine 3 cycles.